Navigation Links
Development of Newer Therapies to Treat Lifestyle Disorders and Reduce the Risk of Co-morbidities is Key to the Expansion of the European Lifestyle Disorders Therapeutics Market, Says Frost & Sullivan
Date:12/2/2009

LONDON, Dec. 2 /PRNewswire-FirstCall/ -- Increasing genomic knowledge will lead to the development of improved therapies to treat lifestyle disorders. In the near future, the European lifestyle disorders therapeutics market is set to witness enhanced therapies and novel drugs to treat such conditions and reduce the risk of co-morbidities.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

New analysis from Frost & Sullivan (http://www.pharma.frost.com), European Lifestyle Disorders Therapeutics Market, finds that the European obesity therapeutics market and European erectile dysfunction therapeutics market earned revenues of $668.1 million and $1234.2 million, respectively, in 2008 and estimates this to reach $1158.1 million and $2,168.2 million in 2015, respectively.

"The future is likely to witness improved therapies and novel drugs to treat lifestyle disorders and lower the risk of co-morbidities," notes Frost & Sullivan Programme Leader Shabeer Hussain. "However, the lack of investment in the current financial climate has dampened the development of newer therapies and technologies, while presenting a major challenge for small biotechnology companies."

As preventive care and personalised medicine come to the fore, more companies are venturing into lifestyle disorders therapeutics. These new developments are likely to present attractive investment opportunities to large biopharmaceutical companies.

Differing regulations are having an impact on drug launches; less price-controlled markets generally witness quicker launches while it takes longer in more regulated markets.

"With the increase in demand for new therapies, the degree of competition among pharmaceutical companies is also intensifying," says Hussain. "However, the requirement of high initial investments against the backdrop of the global economic slowdown and heightened cost containment measures, have led to temporary or complete halt in R&D of new drugs."

Nevertheless, the scenario is optimistic. With advancements in drug discovery, especially in the field of genomics, proteomics and chemical libraries, drug companies are exercising tremendous efforts to bring out novel therapies for lifestyle disorders. This is likely to attract more investments in the future.

"The EU healthcare system should encourage the development of drugs for lifestyle disorders through its healthcare policy by introducing clear reimbursement policies," advises Hussain. "Efforts should also be made to ensure a transparent, EU-wide harmonisation of regulatory policy and an enhanced approval process for lifestyle disorders therapeutics."

If you are interested in more information about this study, please send an e-mail to Katja Feick, Corporate Communications, at katja.feick@frost.com, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

European Lifestyle Disorders Therapeutics Market is part of the Pharmaceuticals & Biotechnology Growth Partnership Services programme, which also includes research in the following markets: European Vaccines Market, European Orphan Drugs Market and, Global Diabetes Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.

European Lifestyle Disorders Therapeutics Market

M3F8



Contact:
Katja Feick
Corporate Communications - Europe
P: +49 (0) 69 7703343
E: katja.feick@frost.com

http://www.frost.com


SOURCE Frost & Sullivan


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers identify role of gene in tumor development, growth and progression
2. HCA Names Joe Sowell Senior Vice President & Chief Development Officer
3. Findings that should speed the development of drugs for Parkinsons disease
4. Nuvo research provides WF10 licensing and development update
5. OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners
6. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
7. Attachment & Emotional Development Expert Teams Up with Miracle Industries, LLC. to Launch Valuable Parenting Resource
8. Developmental drug may help bone fractures heal after radiation exposure
9. Martel Instruments Expands Its Custom Printer Solutions Business in North America; Liz Peirce Named Director of North American Business Development
10. Therap Services to Host Conference on Electronic Documentation, Electronic Signatures and Electronic Health Records for the Developmental Disabilities Community
11. UCSF diabetes, brain tumor stem cell grants to drive development of therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Two years ago, Arizona State ... watched live by 1 million viewers and won numerous honors, including the region’s ... at the Walter Cronkite School of Journalism and Mass Communication are following up ...
(Date:12/2/2016)... Angeles, CA (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, ... lien basis to help personal injury victims find high quality medical care. When the ... Los Angeles area. Fast forward to present day and the now ten-page directory features ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of ... Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, ... Jason brings extensive financial and operational leadership experience to Advanced Inc. He began his ...
(Date:12/2/2016)... ... 2016 , ... Center for Autism and Related Disorders (CARD) Portland today announced ... disorder (ASD) and other developmental disabilities. The group, which is being launched with the ... the opportunity to share stories and advice, seek help, and continue their education on ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... U.S. Surgeon ... interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at ... learned that medicine is about more than making diagnoses and prescribing medicine,” he states. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
(Date:12/2/2016)...  The Addiction Treatment Advisory Group (ATAG), created ... Pharmacy (AMCP), has released detailed findings on how ... addiction crisis, including through improved access to naloxone ... newly released paper, "The Role of Managed Care ... issues around gaps and barriers to addiction treatment ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology: